Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO®

Rhea-AI Summary

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) has received a Notice of Allowance from the United States Patent and Trademark Office for a new patent application covering TARPEYO, strengthening its intellectual property protection and global value proposition.

Positive

• Notice of Allowance for new patent application enhancing TARPEYO's intellectual property protection
• Expected issuance of U.S. patent with Orange Book-listable claims
• CEO's intention to extend patent protection globally

Negative

• None.

STOCKHOLM, Dec. 11, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application no. 18/100,396 entitled "New Pharmaceutical Compositions."  This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.

The allowed claims cover a method of treating IgA nephropathy with a composition that encompasses TARPEYO® (budesonide) delayed release capsules, developed under the name "NEFECON®". Calliditas expects the resulting patent will be Orange Book-listable, with an anticipated expiration date in 2043. The patent, when issued, will be Calliditas' second patent for TARPEYO in the United States. 

Calliditas intends to file corresponding patent applications in additional territories around the world, including Europe and China.

"When issued, our new patent will significantly strengthen TARPEYO's intellectual property protection, further improving its unique value proposition, and providing a basis for an active program of extending patent protection of the NEFECON® franchise globally," said CEO Renée Aguiar-Lucander.

CONTACT:

For further information, please contact:

Åsa Hillsten, Head of IR & Sustainability, Calliditas

Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com

The information in the press release is information that Calliditas is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out above, on December 11, 2023 at 15:15 p.m. CET.

The following files are available for download:

https://mb.cision.com/Main/16574/3891581/2485500.pdf

Patent Press Release Eng

View original content:https://www.prnewswire.com/news-releases/calliditas-receives-notice-of-allowance-for-united-states-patent-application-covering-tarpeyo-302011468.html

SOURCE Calliditas Therapeutics

FAQ

What is the company name and ticker symbol for Calliditas Therapeutics?

The company name is Calliditas Therapeutics AB and the ticker symbols are CALT on Nasdaq and CALTX on Nasdaq Stockholm.

What is the content of the Notice of Allowance received by Calliditas Therapeutics?

The Notice of Allowance is for a new patent application covering TARPEYO, a method of treating IgA nephropathy with a composition that encompasses TARPEYO (budesonide) delayed release capsules.

What is the expected impact of the new patent on TARPEYO's intellectual property protection?

The new patent is expected to significantly strengthen TARPEYO's intellectual property protection, further improving its unique value proposition.

What are the CEO's intentions regarding the new patent?

The CEO intends to file corresponding patent applications in additional territories around the world, including Europe and China, to extend patent protection globally.